Atrial fibrillation (AF) is the most common arrhythmia. The future incidence increases parallel to the life expectancy. Besides novel drugs for stabilisation of the rhythm, new antiarrhythmics for cardioversion have been developed recently. New oral anticoagulants seem to be safe and effective in stroke prevention in patients with AF. The key of AF treatment is an individualized therapy of the patients regarding their symptoms and risk.

We invite investigators to contribute original research articles as well as review articles that explore controversial aspects of AF regarding catheter ablation and anticoagulation. Potential topics include, but are not limited to:

• Rhythm or rate control in AF
• Acute and chronic treatment of AF
• Anticoagulation in AF
• Risk stratification in AF
• Catheter ablation in AF
• AF in young versus elderly patients